CSL Of Australia Could Face Roadblock To U.S. Approval Of Talecris Buy
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL may have trouble getting the approval of U.S. authorities for its acquisition of Talecris Biotherapeutics. The $3.1 billion deal for the blood products company was announced last August, but at least one analyst noted U.S. administrations have changed since then to give greater attention to regulation. The fear is the Federal Trade Commission will block the merger because it would give CSL too much of the blood products market. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.